Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

NCT07476001 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Testosterone cypionate (Tc)
DRUG: ADT with Luteinizing hormone-releasing hormone (LHRH) analog
DRUG: PSMA-617

Sponsor

H. Lee Moffitt Cancer Center and Research Institute